Skip to content

Denosumab

Published: July 26, 2026Updated: August 27, 2026

Denosumab-Dssb is a biosimilar formulation of denosumab, a monoclonal antibody that targets RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). It is used to treat bone-related conditions by inhibiting osteoclast formation, thereby reducing bone resorption and increasing bone density.

Quick summary

Denosumab-Dssb is a biosimilar medication used to treat bone loss and prevent fractures in conditions like osteoporosis and cancer-related bone disease.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

RxNorm
2725498
Generic
Denosumab-Dssb
Class
pin-variant
Brands
Ospomyv, Xbryk
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Treatment of osteoporosis in postmenopausal women and men at high risk for fracture; prevention of skeletal-related events in patients with bone metastases from solid tumors; treatment of bone loss in patients receiving androgen deprivation therapy or aromatase inhibitor therapy; treatment of giant cell tumor of bone; and management of hypercalcemia of malignancy.

Denosumab-Dssb is a fully human monoclonal antibody that binds to RANKL, a protein essential for osteoclast formation, function, and survival. By inhibiting RANKL, the medication reduces bone resorption and increases bone density.

Administered as a subcutaneous injection. Common side effects include musculoskeletal pain, hypocalcemia, and increased risk of infections. Rare but serious adverse effects may include osteonecrosis of the jaw and atypical femoral fractures. Patients should have adequate calcium and vitamin D intake. Not recommended for patients with hypocalcemia. Must be administered by a healthcare professional.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy